P. Klener, Jr.
-
Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma
Jan H. Živný, S. Leahomschi, P. Klener, Jr., J. Živný, M. Haluzík, D. Cibula
2016, Vol. 62, Issue 6, pp. 258-262 -
Molecularly-Targeted and Biological Anti-Cancer Therapy
P. Klener, Jr., Pavel Klener
2012, Vol. 58, Issue 1, pp. 1-6 -
Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Therapeutic Approaches
P. Klener, Jr., L. Anděra, P. Klener, E. Nečas, Jan Živný
2006, Vol. 52, Issue 4, pp. 119-136 -
Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Apoptotic Pathways
P. Klener, Jr., L. Anděra, P. Klener, E. Nečas, Jan Živný
2006, Vol. 52, Issue 1-2, pp. 34-44
The following names might also represent this author:
P. Klener
-
In Vivo Growth of Mantle Cell Lymphoma Xenografts in Immunodeficient Mice Is Positively Regulated by VEGF and Associated with Significant Up-regulation of CD31/PECAM1
Jan Molinský, M. Klánová, B. Maswabi, T. Soukup, M. Trněný, E. Nečas, J. Živný, P. Klener
2013, Vol. 59, Issue 1, pp. 26-31 -
Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Therapeutic Approaches
P. Klener, Jr., L. Anděra, P. Klener, E. Nečas, Jan Živný
2006, Vol. 52, Issue 4, pp. 119-136 -
Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Apoptotic Pathways
P. Klener, Jr., L. Anděra, P. Klener, E. Nečas, Jan Živný
2006, Vol. 52, Issue 1-2, pp. 34-44 -
The Use of Comparative Duplex PCR in Monitoring of Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia
Alena Slavíčková, K. Forsterová, R. Ivánek, J. Černý, P. Klener
2005, Vol. 51, Issue 6, pp. 177-179
Pavel Klener
-
PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population
J. Karolova, M. Radek, K. Helman, M. Spacek, Marek Trněný, Pavel Klener
2020, Vol. 66, Issue 4, pp. 117-122 -
Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma
P. Vockova, M. Svaton, J. Karolova, E. Pokorná, Martin Vokurka, Pavel Klener
2020, Vol. 66, Issue 1, pp. 17-23 -
Molecularly-Targeted and Biological Anti-Cancer Therapy
P. Klener, Jr., Pavel Klener
2012, Vol. 58, Issue 1, pp. 1-6
